Clinical trials
Liver Cell Carcinoma clinical trials
Below are recruiting liver cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 443 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07559045RecruitingPhase 2
Chemo-Immunotherapy Plus Radiation vs Standard Treatment for Advanced Esophageal Cancer
This trial compares two treatment approaches for advanced esophageal squamous cell carcinoma (a type of cancer that starts in the lining of the food tube). One group receives chemotherapy combined with an immunotherapy drug before radiation; the other receives chemotherapy and radiation at the same time. The goal is to see which approach works better.
Zunyi, GuizhouAges 18–75 - NCT07312578Enrolling by invitationPhase 2
Targeted drugs plus chemo before surgery for esophageal cancer
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
Beijing, Beijing MunicipalityAges 18–70 - NCT07290010RecruitingPhase 2
Iparomlimab plus chemotherapy for advanced esophageal cancer
This trial tests a combination of two immunotherapy drugs (Iparomlimab and Tuvonralimab) with chemotherapy as a first treatment for advanced esophageal squamous cell carcinoma. It aims to see if this combination is safe and effective for people whose cancer cannot be removed by surgery or has spread.
Shijiazhuang, HebeiAges 18 years+ - NCT07219576RecruitingPhase 1/Phase 2
Study of Retifanlimab and Ruxolitinib for Certain Cancers
This trial tests a combination of two drugs, retifanlimab and ruxolitinib, for people with advanced kidney cancer (clear cell renal cell carcinoma) or lung cancer (non-small cell lung carcinoma) whose cancer has grown after previous treatment with a type of immunotherapy called PD-1/PD-L1 inhibitors. The goal is to see if this combination can help when standard treatments are no longer working.
La Jolla, CaliforniaAges Any age - NCT07205731RecruitingPhase 2
Tislelizumab for older adults with advanced esophageal cancer
This trial tests a drug called tislelizumab (an immunotherapy) in older adults (70+) with advanced esophageal cancer who cannot have standard chemotherapy. The goal is to see if the drug can slow or shrink the cancer safely.
Annecy, Epagny Metz-TessyAges 70 years+ - NCT07189871RecruitingPhase 1/Phase 2
Targeted radiation therapy for advanced solid tumors
This study tests a new radioactive treatment (177Lu-BetaBart) for people with certain advanced solid tumors that have stopped responding to standard treatments. It aims to see if this targeted therapy can slow or stop tumor growth.
Dothan, AlabamaAges 18 years+ - NCT07039162RecruitingPhase 2
Tislelizumab with chemo and radiation before surgery for advanced esophageal cancer
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and radiation, followed by surgery, for people with advanced esophageal cancer that cannot be removed right away. It aims to see if this approach can help shrink the tumor enough to allow surgery.
Kaohsiung CityAges 20 years+ - NCT06446726RecruitingPhase 2
Low-dose radiation, chemo, and immunotherapy before esophageal cancer surgery
This trial tests a combination of low-dose radiation, chemotherapy, and immunotherapy before surgery for esophageal cancer. The goal is to see if this approach helps shrink the tumor and improve outcomes.
Chengdu, SichuanAges 18–75 - NCT06642220RecruitingPhase 2
Y-90 radioembolization for kidney cancer
This trial tests a procedure called Y-90 radioembolization for patients with kidney cancer tumors larger than 4 cm who cannot have or choose not to have surgery. The treatment delivers tiny radioactive beads through a blood vessel to the tumor to destroy cancer cells while limiting damage to healthy tissue.
London, OntarioAges 18 years+ - NCT06567314RecruitingPhase 2
Study of Ivonescimab for advanced skin or prostate cancer
This study tests a new immunotherapy medicine, ivonescimab, in people with advanced skin cancer or advanced prostate cancer. It looks at how safe and effective the drug is.
Houston, TexasAges 18 years+ - NCT06364384RecruitingPhase 2
Chemo, radiation, and immunotherapy for rectal squamous cell carcinoma
This trial tests a combination of chemotherapy (cisplatin and 5-FU), radiation, and an immunotherapy drug (PD-1 antibody) for people with a rare type of rectal cancer that hasn't spread. The goal is to see if this treatment can shrink or eliminate the cancer.
Guangzhou, GuangdongAges 18–75 - NCT06329869RecruitingPhase 2
A study of sacituzumab govitecan for advanced esophageal cancer
This trial tests a drug called sacituzumab govitecan for people with advanced esophageal squamous cell carcinoma that has already been treated with chemotherapy and immunotherapy. The drug targets a protein called Trop-2 on cancer cells to try to stop tumor growth.
TaipeiAges 18 years+ - NCT05268614RecruitingPhase 2
Risk-based reduced chemo and radiation for HPV throat cancer
This trial tests whether using a lower intensity (reduced) chemo-radiation plan can work for some people with HPV-related oropharyngeal (throat) cancer without losing effectiveness. It may help reduce side effects while still controlling the cancer.
Gainesville, FloridaAges 18 years+ - NCT06814496RecruitingPhase 1/Phase 2
Radiation and immunotherapy combo for DLL3-positive cancers
This trial combines radiation with an immunotherapy drug called tarlatamab to treat cancers that make a protein called DLL3. The goal is to see if this combination works better than either treatment alone for people with certain types of lung cancer and other tumors that have not responded to prior therapy.
Gilbert, ArizonaAges 18–99 - NCT06342167RecruitingPhase 2
Immunotherapy and radiation with nutrition support for esophageal cancer
This trial combines an immunotherapy drug (a PD-1 inhibitor) with radiation therapy and special nutrition drinks to treat esophageal cancer that cannot be removed with surgery. The goal is to see if this combination is safe and effective in helping patients live longer and feel better.
Beijing, Beijing MunicipalityAges 18–80 - NCT06383728RecruitingPhase 2
Targeted therapy before surgery for EGFR-mutated lung cancer
This trial tests if taking a targeted therapy drug before surgery can help shrink tumors in people with a specific type of lung cancer called EGFR-mutated squamous cell carcinoma that can be removed with surgery. The goal is to see if this approach improves outcomes.
Guangzhou, GuangdongAges 18–75 - NCT07670858RecruitingPhase 1
Study of a new skin cream for basal cell carcinoma
This study tests an experimental drug called FLD-103 injected into a specific type of skin cancer (nodular basal cell carcinoma) that hasn't been treated before. The goal is to see if it helps remove the cancer before final surgery.
Bowling Green, KentuckyAges 18–85 - NCT05214222RecruitingPhase 2
New treatment for advanced esophageal cancer after past therapy
This Phase 2 trial tests penpulimab plus chemotherapy (with or without an added targeted pill called anlotinib) in people with advanced esophageal squamous cell carcinoma. It aims to slow tumor growth and improve outcomes, especially for patients who can’t have curative surgery or radiation.
Guangzhou, GuangdongAges 18–75 - NCT07333274RecruitingPhase 3
Radiation plus nimotuzumab for head and neck cancer
This trial compares radiation therapy alone versus radiation therapy plus a targeted drug called nimotuzumab for people with advanced head and neck cancer who cannot take cisplatin chemotherapy. The goal is to see if adding nimotuzumab improves outcomes.
Shandong, ProvinceAges 18 years+ - NCT07133958Recruiting
Testing NAIC for advanced mouth and throat cancer
This study looks at how well NAIC treatment helps shrink advanced mouth or throat cancer. It aims to find patterns in how tumors respond to treatment.
Guangzhou, GuangdongAges 18–80 - NCT07042295RecruitingPhase 2
Amivantamab or Cetuximab for Skin Cancer in People with Weakened Immune Systems
This trial tests two drugs, amivantamab with hyaluronidase or cetuximab, in people with weakened immune systems who have advanced skin cancer (squamous cell carcinoma). The goal is to see if these treatments can help shrink or control the cancer.
Birmingham, AlabamaAges 18 years+ - NCT06981325RecruitingPhase 2
Cemiplimab for advanced basal cell carcinoma
This trial tests cemiplimab, an immunotherapy drug, as a first treatment for advanced basal cell carcinoma that cannot be removed with surgery or radiation. The goal is to see if it can shrink or control the cancer.
ErfurtAges 18 years+ - NCT05173246RecruitingPhase 2
First-line treatment study for advanced small cell esophageal cancer
This Phase 2 trial tests JS001 plus TP as a first treatment for people with advanced or unresectable small cell esophageal cancer. It aims to see how well this combination controls the cancer and improves outcomes compared with starting treatment with standard options.
Guangzhou, GuangdongAges 18–75 - NCT06004336RecruitingPhase 2
Maintenance therapy after radiation for limited spread kidney cancer
This trial tests whether giving a maintenance medication (pembrolizumab) after targeted radiation helps keep kidney cancer that has spread to a few spots (5 or fewer) from growing. You would receive radiation to each spot and then be randomly assigned to receive either the medication or a placebo (inactive substance) for up to about 2 years.
Houston, TexasAges 18 years+
Hear when a new Liver Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for liver cell carcinoma?
- Yes. Clin2 currently lists 443 recruiting liver cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a liver cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a liver cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.